<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01622504</url>
  </required_header>
  <id_info>
    <org_study_id>MVP005-CLN-001</org_study_id>
    <nct_id>NCT01622504</nct_id>
  </id_info>
  <brief_title>Naloxone Nasal Spray Pharmacokinetic Study</brief_title>
  <official_title>A Phase I Single Dose, Open Label, Randomized, Three Period Crossover Pilot Study to Compare the Pharmacokinetics, Safety and Tolerability of MVP005 Intranasal Spray With Intranasal Administration of Naloxone Solution for Injection in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitovie Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitovie Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the pharmacokinetics of naloxone when administered as the Mitovie
      nasal spray (Test Product) and as a solution for injection (Comparator Product) administered
      intranasally using a mucosal atomization device (MAD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Naloxone hydrochloride is currently only recommended and licensed for intravenous,
      intramuscular and subcutaneous administration. It has also been used by intranasal
      administration (off-label use) when the intravenous route is not suitable by administering
      the Solution for Injection using a mucosal atomization device (MAD). However, due to the
      volume of naloxone solution administered this way, some of it may be inadvertently swallowed
      and not absorbed into the nasal mucosa and the product requires administration by medically
      trained personnel. The study aims to investigate intranasal administration of naloxone using
      a more concentrated solution and a nasal delivery device.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>0, 5, 10, 15, 20, 30 and 45 minutes and 1.00, 1.50, 2.00, 3.00, 4.00, 6.00, 8.00 and 12.00 hours for each arm</time_frame>
    <description>Plasma concentration time profiles and area under the curve (AUC), maximum concentation (Cmax), Time to maximum concentration (Tmax), elimination rate constant (Kel) and terminal half life (t1/2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>14 days</time_frame>
    <description>Continuous adverse event monitoring during the study with prompted assessments in the 12 hours post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Examination</measure>
    <time_frame>14 days</time_frame>
    <description>Complete physical examination at screening and final follow-up and specific nasal examination post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs</measure>
    <time_frame>14 days</time_frame>
    <description>Vital signs at screening, final follow-up and pre- and post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECGs</measure>
    <time_frame>14 days</time_frame>
    <description>ECGs at screening and final follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Laboratory Tests</measure>
    <time_frame>14 days</time_frame>
    <description>Haematology, biochemistry and urinalysis at screening and final follow-up</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Opioid Overdose</condition>
  <arm_group>
    <arm_group_label>Test Product Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Product Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MVP005</intervention_name>
    <description>2 mg single dose administered intranasally</description>
    <arm_group_label>Test Product Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MVP005</intervention_name>
    <description>4 mg single dose administered intranasally</description>
    <arm_group_label>Test Product Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone hydrochloride solution for injection with mucosal atomization device</intervention_name>
    <description>2 mg single dose administered intranasally</description>
    <arm_group_label>Comparator Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  18-60 50 years of age

          -  Provide written informed consent prior to completing any study specific procedure.

          -  Body Mass Index (BMI) range 18.5-30 kg/m2

          -  Clinically acceptable medical history, clinical laboratory evaluations, complete
             physical examination, vital signs and 12 lead ECG

          -  Using reliable contraception

        Exclusion Criteria:

          -  Intranasal problems

          -  Taking prescribed or over the counter medications

          -  Intake of alcohol, methyl-xanthines or grapefruit or strenuous exercise concurrent
             with treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdullah Hiyari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IPRC, Jordan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rana Hassan, MSc</last_name>
    <phone>+96265627651</phone>
    <email>r.hassan@iprc.com.jo</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Halah Zqqout, BSc</last_name>
    <phone>+96265627651</phone>
    <email>h.zqqout@iprc.com.jo</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>International Pharmaceutical Research Center (IPRC)</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rana Hassan, MSc</last_name>
      <phone>+96265627651</phone>
      <email>r.hassan@iprc.com.jo</email>
    </contact>
    <contact_backup>
      <last_name>Halah Zqqout, BSc</last_name>
      <phone>+96265627651</phone>
      <email>h.zqqout@iprc.com.jo</email>
    </contact_backup>
    <investigator>
      <last_name>Abdullah Hiyari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2012</study_first_posted>
  <last_update_submitted>June 19, 2012</last_update_submitted>
  <last_update_submitted_qc>June 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intranasal</keyword>
  <keyword>nasal spray</keyword>
  <keyword>opioid</keyword>
  <keyword>overdose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug Overdose</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

